Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome positive chronic myelogenous leukaemia (CML).

Treatment is indicated for adults with chronic-phase and accelerated-phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

View Tasigna drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more